ID   ACTB_HUMAN              Reviewed;         375 AA.
AC   P60709; P02570; P70514; P99021; Q11211; Q64316; Q75MN2; Q96B34; Q96HG5;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   18-JUN-2025, entry version 216.
DE   RecName: Full=Actin, cytoplasmic 1;
DE            EC=3.6.4.- {ECO:0000250|UniProtKB:P68137};
DE   AltName: Full=Beta-actin;
DE   Contains:
DE     RecName: Full=Actin, cytoplasmic 1, N-terminally processed;
GN   Name=ACTB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6322116; DOI=10.1093/nar/12.3.1687;
RA   Ponte P., Ng S.Y., Engel J., Gunning P., Kedes L.;
RT   "Evolutionary conservation in the untranslated regions of actin mRNAs: DNA
RT   sequence of a human beta-actin cDNA.";
RL   Nucleic Acids Res. 12:1687-1696(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2994062; DOI=10.1073/pnas.82.18.6133;
RA   Nakajima-Iijima S., Hamada H., Reddy P., Kakunaga T.;
RT   "Molecular structure of the human cytoplasmic beta-actin gene: interspecies
RT   homology of sequences in the introns.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6133-6137(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1734024; DOI=10.1083/jcb.116.4.933;
RA   Ohmori H., Toyama S., Toyama S.;
RT   "Direct proof that the primary site of action of cytochalasin on cell
RT   motility processes is actin.";
RL   J. Cell Biol. 116:933-941(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Eye, Kidney, Muscle, Pancreas, Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-28.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-18; 29-37; 40-50; 85-95; 148-177; 184-191; 197-206;
RP   292-312 AND 316-326, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT
RP   ASP-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (JUN-2005) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 19-62; 85-113; 184-191; 197-206; 216-254; 291-312;
RP   316-326 AND 360-372, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 252-375.
RX   PubMed=6842590; DOI=10.1016/0022-2836(83)90117-1;
RA   Hanukoglu I., Tanese N., Fuchs E.;
RT   "Complementary DNA sequence of a human cytoplasmic actin. Interspecies
RT   divergence of 3' non-coding regions.";
RL   J. Mol. Biol. 163:673-678(1983).
RN   [11]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH DHX9.
RX   PubMed=11687588; DOI=10.1074/jbc.m109393200;
RA   Zhang S., Buder K., Burkhardt C., Schlott B., Goerlach M., Grosse F.;
RT   "Nuclear DNA helicase II/RNA helicase A binds to filamentous actin.";
RL   J. Biol. Chem. 277:843-853(2002).
RN   [12]
RP   IDENTIFICATION IN A COMPLEX WITH RAN; XPO6 AND PFN1, AND INTERACTION WITH
RP   XPO6.
RX   PubMed=14592989; DOI=10.1093/emboj/cdg565;
RA   Stueven T., Hartmann E., Goerlich D.;
RT   "Exportin 6: a novel nuclear export receptor that is specific for
RT   profilin.actin complexes.";
RL   EMBO J. 22:5928-5940(2003).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [14]
RP   INTERACTION WITH EMD.
RX   PubMed=15328537; DOI=10.1371/journal.pbio.0020231;
RA   Holaska J.M., Kowalski A.K., Wilson K.L.;
RT   "Emerin caps the pointed end of actin filaments: evidence for an actin
RT   cortical network at the nuclear inner membrane.";
RL   PLoS Biol. 2:1354-1362(2004).
RN   [15]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [16]
RP   INTERACTION WITH GCSAM.
RX   PubMed=17823310; DOI=10.1182/blood-2007-04-087775;
RA   Lu X., Chen J., Malumbres R., Cubedo Gil E., Helfman D.M., Lossos I.S.;
RT   "HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and
RT   mediates the effects of IL-6 on cell migration.";
RL   Blood 110:4268-4277(2007).
RN   [17]
RP   IDENTIFICATION IN A MRNP GRANULE COMPLEX, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND SUBCELLULAR LOCATION.
RX   PubMed=17289661; DOI=10.1074/mcp.m600346-mcp200;
RA   Joeson L., Vikesaa J., Krogh A., Nielsen L.K., Hansen T., Borup R.,
RA   Johnsen A.H., Christiansen J., Nielsen F.C.;
RT   "Molecular composition of IMP1 ribonucleoprotein granules.";
RL   Mol. Cell. Proteomics 6:798-811(2007).
RN   [18]
RP   IDENTIFICATION IN THE BAF COMPLEX, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18765789; DOI=10.1101/gad.471408;
RA   Lange M., Kaynak B., Forster U.B., Toenjes M., Fischer J.J., Grimm C.,
RA   Schlesinger J., Just S., Dunkel I., Krueger T., Mebus S., Lehrach H.,
RA   Lurz R., Gobom J., Rottbauer W., Abdelilah-Seyfried S., Sperling S.;
RT   "Regulation of muscle development by DPF3, a novel histone acetylation and
RT   methylation reader of the BAF chromatin remodeling complex.";
RL   Genes Dev. 22:2370-2384(2008).
RN   [19]
RP   CROSS-LINK BETWEEN LYS-50 AND GLU-270 BY V.CHOLERAE TOXIN RTXA (MICROBIAL
RP   INFECTION).
RX   PubMed=19015515; DOI=10.1073/pnas.0808082105;
RA   Kudryashov D.S., Durer Z.A., Ytterberg A.J., Sawaya M.R., Pashkov I.,
RA   Prochazkova K., Yeates T.O., Loo R.R., Loo J.A., Satchell K.J., Reisler E.;
RT   "Connecting actin monomers by iso-peptide bond is a toxicity mechanism of
RT   the Vibrio cholerae MARTX toxin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:18537-18542(2008).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ASP-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   RETRACTED PAPER.
RX   PubMed=19377461; DOI=10.1038/nature07954;
RA   Fujiki R., Chikanishi T., Hashiba W., Ito H., Takada I., Roeder R.G.,
RA   Kitagawa H., Kato S.;
RT   "GlcNAcylation of a histone methyltransferase in retinoic-acid-induced
RT   granulopoiesis.";
RL   Nature 459:455-459(2009).
RN   [22]
RP   RETRACTION NOTICE OF PUBMED:19377461.
RX   PubMed=24336203; DOI=10.1038/nature12896;
RA   Fujiki R., Chikanishi T., Hashiba W., Ito H., Takada I., Roeder R.G.,
RA   Kitagawa H., Kato S.;
RT   "Retraction: GlcNAcylation of a histone methyltransferase in retinoic-acid-
RT   induced granulopoiesis.";
RL   Nature 505:574-574(2014).
RN   [23]
RP   INTERACTION WITH FAM107A.
RX   PubMed=21969592; DOI=10.1073/pnas.1103318108;
RA   Schmidt M.V., Schuelke J.P., Liebl C., Stiess M., Avrabos C., Bock J.,
RA   Wochnik G.M., Davies H.A., Zimmermann N., Scharf S.H., Truembach D.,
RA   Wurst W., Zieglgaensberger W., Turck C., Holsboer F., Stewart M.G.,
RA   Bradke F., Eder M., Mueller M.B., Rein T.;
RT   "Tumor suppressor down-regulated in renal cell carcinoma 1 (DRR1) is a
RT   stress-induced actin bundling factor that modulates synaptic efficacy and
RT   cognition.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:17213-17218(2011).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ASP-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 AND ASP-2, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [26]
RP   INTERACTION WITH ERBB2.
RX   PubMed=21555369; DOI=10.1158/0008-5472.can-10-3504;
RA   Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H., Chen H.Y.,
RA   Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P., Lien H.C., Tsai C.H.,
RA   Hung M.C.;
RT   "Nuclear ErbB2 enhances translation and cell growth by activating
RT   transcription of ribosomal RNA genes.";
RL   Cancer Res. 71:4269-4279(2011).
RN   [27]
RP   METHYLATION AT LYS-84, AND DEMETHYLATION BY ALKBH4.
RX   PubMed=23673617; DOI=10.1038/ncomms2863;
RA   Li M.M., Nilsen A., Shi Y., Fusser M., Ding Y.H., Fu Y., Liu B., Niu Y.,
RA   Wu Y.S., Huang C.M., Olofsson M., Jin K.X., Lv Y., Xu X.Z., He C.,
RA   Dong M.Q., Rendtlew Danielsen J.M., Klungland A., Yang Y.G.;
RT   "ALKBH4-dependent demethylation of actin regulates actomyosin dynamics.";
RL   Nat. Commun. 4:1832-1832(2013).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ASP-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [29]
RP   CROSS-LINK BY V.CHOLERAE TOXIN RTXA (MICROBIAL INFECTION).
RX   PubMed=26228148; DOI=10.1126/science.aab4090;
RA   Heisler D.B., Kudryashova E., Grinevich D.O., Suarez C., Winkelman J.D.,
RA   Birukov K.G., Kotha S.R., Parinandi N.L., Vavylonis D., Kovar D.R.,
RA   Kudryashov D.S.;
RT   "ACD toxin-produced actin oligomers poison formin-controlled actin
RT   polymerization.";
RL   Science 349:535-539(2015).
RN   [30]
RP   INTERACTION WITH FAM107A.
RX   PubMed=28604741; DOI=10.1038/onc.2017.181;
RA   Mu P., Akashi T., Lu F., Kishida S., Kadomatsu K.;
RT   "A novel nuclear complex of DRR1, F-actin and COMMD1 involved in NF-kappaB
RT   degradation and cell growth suppression in neuroblastoma.";
RL   Oncogene 36:5745-5756(2017).
RN   [31]
RP   ACETYLATION AT ASP-2.
RX   PubMed=30028079; DOI=10.1111/febs.14605;
RA   Wiame E., Tahay G., Tyteca D., Vertommen D., Stroobant V., Bommer G.T.,
RA   Van Schaftingen E.;
RT   "NAT6 acetylates the N-terminus of different forms of actin.";
RL   FEBS J. 285:3299-3316(2018).
RN   [32]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=29925947; DOI=10.1038/s41586-018-0237-5;
RA   Schrank B.R., Aparicio T., Li Y., Chang W., Chait B.T., Gundersen G.G.,
RA   Gottesman M.E., Gautier J.;
RT   "Nuclear ARP2/3 drives DNA break clustering for homology-directed repair.";
RL   Nature 559:61-66(2018).
RN   [33]
RP   FUNCTION, AND ACETYLATION AT ASP-2.
RX   PubMed=29581253; DOI=10.1073/pnas.1718336115;
RA   Drazic A., Aksnes H., Marie M., Boczkowska M., Varland S., Timmerman E.,
RA   Foyn H., Glomnes N., Rebowski G., Impens F., Gevaert K., Dominguez R.,
RA   Arnesen T.;
RT   "NAA80 is actin's N-terminal acetyltransferase and regulates cytoskeleton
RT   assembly and cell motility.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:4399-4404(2018).
RN   [34]
RP   METHYLATION AT HIS-73.
RX   PubMed=30526847; DOI=10.7554/elife.37921;
RA   Kwiatkowski S., Seliga A.K., Vertommen D., Terreri M., Ishikawa T.,
RA   Grabowska I., Tiebe M., Teleman A.A., Jagielski A.K., Veiga-da-Cunha M.,
RA   Drozak J.;
RT   "SETD3 protein is the actin-specific histidine N-methyltransferase.";
RL   Elife 7:0-0(2018).
RN   [35]
RP   OXIDATION AT MET-44 AND MET-47.
RX   PubMed=29343822; DOI=10.1038/s41598-017-17943-5;
RA   Wu H., Yesilyurt H.G., Yoon J., Terman J.R.;
RT   "The MICALs are a Family of F-actin Dismantling Oxidoreductases Conserved
RT   from Drosophila to Humans.";
RL   Sci. Rep. 8:937-937(2018).
RN   [36]
RP   PROTEOLYTIC CLEAVAGE BY ACTMAP, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   ACETYLATION AT MET-1.
RX   PubMed=36173861; DOI=10.1126/science.abq5082;
RA   Haahr P., Galli R.A., van den Hengel L.G., Bleijerveld O.B.,
RA   Kazokaite-Adomaitiene J., Song J.Y., Kroese L.J., Krimpenfort P.,
RA   Baltissen M.P., Vermeulen M., Ottenheijm C.A.C., Brummelkamp T.R.;
RT   "Actin maturation requires the ACTMAP/C19orf54 protease.";
RL   Science 377:1533-1537(2022).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 66-88 IN COMPLEX WITH SETD3,
RP   METHYLATION AT HIS-73, AND MUTAGENESIS OF TYR-69; ILE-71; HIS-73; ASP-80;
RP   ASP-81 AND MET-82.
RX   PubMed=30785395; DOI=10.7554/elife.43676;
RA   Guo Q., Liao S., Kwiatkowski S., Tomaka W., Yu H., Wu G., Tu X., Min J.,
RA   Drozak J., Xu C.;
RT   "Structural insights into SETD3-mediated histidine methylation on beta-
RT   actin.";
RL   Elife 8:0-0(2019).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.69 ANGSTROMS) OF 67-75 IN COMPLEX WITH SETD3,
RP   METHYLATION AT HIS-73, AND MUTAGENESIS OF ILE-71; GLY-74 AND TRP-79.
RX   PubMed=30626964; DOI=10.1038/s41586-018-0821-8;
RA   Wilkinson A.W., Diep J., Dai S., Liu S., Ooi Y.S., Song D., Li T.M.,
RA   Horton J.R., Zhang X., Liu C., Trivedi D.V., Ruppel K.M.,
RA   Vilches-Moure J.G., Casey K.M., Mak J., Cowan T., Elias J.E.,
RA   Nagamine C.M., Spudich J.A., Cheng X., Carette J.E., Gozani O.;
RT   "SETD3 is an actin histidine methyltransferase that prevents primary
RT   dystocia.";
RL   Nature 565:372-376(2019).
RN   [39] {ECO:0007744|PDB:6OX0, ECO:0007744|PDB:6OX1, ECO:0007744|PDB:6OX2, ECO:0007744|PDB:6OX3, ECO:0007744|PDB:6OX4, ECO:0007744|PDB:6OX5}
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 66-80 IN COMPLEX WITH SETD3,
RP   METHYLATION AT HIS-73, AND MUTAGENESIS OF HIS-73.
RX   PubMed=31388018; DOI=10.1038/s41467-019-11554-6;
RA   Dai S., Horton J.R., Woodcock C.B., Wilkinson A.W., Zhang X., Gozani O.,
RA   Cheng X.;
RT   "Structural basis for the target specificity of actin histidine
RT   methyltransferase SETD3.";
RL   Nat. Commun. 10:3541-3541(2019).
RN   [40] {ECO:0007744|PDB:6WK1, ECO:0007744|PDB:6WK2}
RP   X-RAY CRYSTALLOGRAPHY (1.76 ANGSTROMS) OF 66-88 IN COMPLEX WITH SETD3, AND
RP   MUTAGENESIS OF HIS-73.
RX   PubMed=32503840; DOI=10.1074/jbc.ra120.014072;
RA   Dai S., Holt M.V., Horton J.R., Woodcock C.B., Patel A., Zhang X.,
RA   Young N.L., Wilkinson A.W., Cheng X.;
RT   "Characterization of SETD3 methyltransferase-mediated protein methionine
RT   methylation.";
RL   J. Biol. Chem. 295:10901-10910(2020).
RN   [41] {ECO:0007744|PDB:6V62, ECO:0007744|PDB:6V63}
RP   X-RAY CRYSTALLOGRAPHY (2.02 ANGSTROMS) OF 66-88 IN COMPLEX WITH SETD3.
RX   PubMed=31911441; DOI=10.1074/jbc.ra119.012319;
RA   Dai S., Horton J.R., Wilkinson A.W., Gozani O., Zhang X., Cheng X.;
RT   "An engineered variant of SETD3 methyltransferase alters target specificity
RT   from histidine to lysine methylation.";
RL   J. Biol. Chem. 295:2582-2589(2020).
RN   [42] {ECO:0007744|PDB:8RX1}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.57 ANGSTROMS) IN COMPLEX WITH MZT1;
RP   MZT2A; CDK5RAP2 AND THE GAMMA-TUBULIN RING COMPLEX, FUNCTION, AND SUBUNIT.
RX   PubMed=39321809; DOI=10.1016/j.devcel.2024.09.001;
RA   Serna M., Zimmermann F., Vineethakumari C., Gonzalez-Rodriguez N.,
RA   Llorca O., Luders J.;
RT   "CDK5RAP2 activates microtubule nucleator gammaTuRC by facilitating
RT   template formation and actin release.";
RL   Dev. Cell 59:3175-3188.e8(2024).
RN   [43] {ECO:0007744|PDB:8VRD, ECO:0007744|PDB:8VRJ, ECO:0007744|PDB:8VRK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (7.00 ANGSTROMS) IN COMPLEXES WITH MZT1;
RP   TUBA1B; TUBB3 AND THE GAMMA-TUBULIN RING COMPLEX, FUNCTION, AND SUBUNIT.
RX   PubMed=38609661; DOI=10.1038/s41594-024-01264-z;
RA   Aher A., Urnavicius L., Xue A., Neselu K., Kapoor T.M.;
RT   "Structure of the gamma-tubulin ring complex-capped microtubule.";
RL   Nat. Struct. Mol. Biol. 31:1124-1133(2024).
RN   [44]
RP   VARIANT THC8 LYS-364, INVOLVEMENT IN THC8, AND INTERACTION WITH PFN1.
RX   PubMed=10411937; DOI=10.1073/pnas.96.15.8693;
RA   Nunoi H., Yamazaki T., Tsuchiya H., Kato S., Malech H.L., Matsuda I.,
RA   Kanegasaki S.;
RT   "A heterozygous mutation of beta-actin associated with neutrophil
RT   dysfunction and recurrent infection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:8693-8698(1999).
RN   [45]
RP   VARIANT DDS1 TRP-183, AND CHARACTERIZATION OF VARIANT DDS1 TRP-183.
RX   PubMed=16685646; DOI=10.1086/504271;
RA   Procaccio V., Salazar G., Ono S., Styers M.L., Gearing M., Davila A.,
RA   Jimenez R., Juncos J., Gutekunst C.-A., Meroni G., Fontanella B.,
RA   Sontag E., Sontag J.-M., Faundez V., Wainer B.H.;
RT   "A mutation of beta -actin that alters depolymerization dynamics is
RT   associated with autosomal dominant developmental malformations, deafness,
RT   and dystonia.";
RL   Am. J. Hum. Genet. 78:947-960(2006).
RN   [46]
RP   VARIANTS BRWS1 ASP-12; VAL-65; CYS-196 AND HIS-196.
RX   PubMed=22366783; DOI=10.1038/ng.1091;
RA   Riviere J.B., van Bon B.W., Hoischen A., Kholmanskikh S.S., O'Roak B.J.,
RA   Gilissen C., Gijsen S., Sullivan C.T., Christian S.L., Abdul-Rahman O.A.,
RA   Atkin J.F., Chassaing N., Drouin-Garraud V., Fry A.E., Fryns J.P.,
RA   Gripp K.W., Kempers M., Kleefstra T., Mancini G.M., Nowaczyk M.J.,
RA   van Ravenswaaij-Arts C.M., Roscioli T., Marble M., Rosenfeld J.A.,
RA   Siu V.M., de Vries B.B., Shendure J., Verloes A., Veltman J.A.,
RA   Brunner H.G., Ross M.E., Pilz D.T., Dobyns W.B.;
RT   "De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter
RT   syndrome.";
RL   Nat. Genet. 44:440-444(2012).
RN   [47]
RP   CHARACTERIZATION OF VARIANT DDS1 TRP-183, CHARACTERIZATION OF VARIANT THC8
RP   LYS-364, CATALYTIC ACTIVITY, FUNCTION, AND INTERACTION WITH PFN1.
RX   PubMed=25255767; DOI=10.1111/febs.13068;
RA   Hundt N., Preller M., Swolski O., Ang A.M., Mannherz H.G., Manstein D.J.,
RA   Mueller M.;
RT   "Molecular mechanisms of disease-related human beta-actin mutations p.R183W
RT   and p.E364K.";
RL   FEBS J. 281:5279-5291(2014).
RN   [48]
RP   VARIANT DDS1 TRP-183.
RX   PubMed=28487785; DOI=10.1155/2017/9184265;
RA   Conboy E., Vairo F., Waggoner D., Ober C., Das S., Dhamija R., Klee E.W.,
RA   Pichurin P.;
RT   "Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia,
RT   Hearing Loss, and Developmental Delay without Midline Malformation.";
RL   Case Rep. Genet. 2017:9184265-9184265(2017).
RN   [49]
RP   VARIANT BNS CYS-147, VARIANT SER-147, AND INVOLVEMENT IN BNS.
RX   PubMed=28347698; DOI=10.1016/j.jid.2017.03.017;
RA   Cai E.D., Sun B.K., Chiang A., Rogers A., Bernet L., Cheng B., Teng J.,
RA   Rieger K.E., Sarin K.Y.;
RT   "Postzygotic Mutations in Beta-Actin Are Associated with Becker's Nevus and
RT   Becker's Nevus Syndrome.";
RL   J. Invest. Dermatol. 137:1795-1798(2017).
RN   [50]
RP   VARIANT DDS1 TRP-183.
RX   PubMed=29788902; DOI=10.1186/s11689-018-9235-z;
RA   Skogseid I.M., Roesby O., Konglund A., Connelly J.P., Nedregaard B.,
RA   Jablonski G.E., Kvernmo N., Stray-Pedersen A., Glover J.C.;
RT   "Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows
RT   striatal dopaminergic dysfunction and response to pallidal stimulation.";
RL   J. Neurodev. Disord. 10:17-17(2018).
RN   [51]
RP   VARIANTS THC8 ARG-313 AND 338-SER--ILE-341 DEL, AND INVOLVEMENT IN THC8.
RX   PubMed=30315159; DOI=10.1038/s41467-018-06713-0;
RA   Latham S.L., Ehmke N., Reinke P.Y.A., Taft M.H., Eicke D., Reindl T.,
RA   Stenzel W., Lyons M.J., Friez M.J., Lee J.A., Hecker R., Fruehwald M.C.,
RA   Becker K., Neuhann T.M., Horn D., Schrock E., Niehaus I., Sarnow K.,
RA   Gruetzmann K., Gawehn L., Klink B., Rump A., Chaponnier C., Figueiredo C.,
RA   Knoefler R., Manstein D.J., Di Donato N.;
RT   "Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopenia.";
RL   Nat. Commun. 9:4250-4250(2018).
RN   [52]
RP   ERRATUM OF PUBMED:30315159.
RX   PubMed=30451859; DOI=10.1038/s41467-018-07404-6;
RA   Latham S.L., Ehmke N., Reinke P.Y.A., Taft M.H., Eicke D., Reindl T.,
RA   Stenzel W., Lyons M.J., Friez M.J., Lee J.A., Hecker R., Fruehwald M.C.,
RA   Becker K., Neuhann T.M., Horn D., Schrock E., Niehaus I., Sarnow K.,
RA   Gruetzmann K., Gawehn L., Klink B., Rump A., Chaponnier C., Figueiredo C.,
RA   Knoefler R., Manstein D.J., Di Donato N.;
RL   Nat. Commun. 9:4930-4930(2018).
RN   [53]
RP   VARIANT BRWS1 ALA-70, AND VARIANT THC8 PHE-171.
RX   PubMed=30733661; DOI=10.1159/000492267;
RA   Sandestig A., Green A., Jonasson J., Vogt H., Wahlstroem J., Pepler A.,
RA   Ellnebo K., Biskup S., Stefanova M.;
RT   "Could Dissimilar Phenotypic Effects of ACTB Missense Mutations Reflect the
RT   Actin Conformational Change? Two Novel Mutations and Literature Review.";
RL   Mol. Syndromol. 9:259-265(2019).
RN   [54]
RP   VARIANTS CSMH ASP-111; HIS-137; ALA-146; VAL-146; ASP-146; SER-146; SER-147
RP   AND CYS-147, AND INVOLVEMENT IN CSMH.
RX   PubMed=32170967; DOI=10.1111/cup.13683;
RA   Atzmony L., Ugwu N., Zaki T.D., Antaya R.J., Choate K.A.;
RT   "Post-zygotic ACTB mutations underlie congenital smooth muscle
RT   hamartomas.";
RL   J. Cutan. Pathol. 47:681-685(2020).
RN   [55]
RP   VARIANT DDS1 TRP-183.
RX   PubMed=35005077; DOI=10.1002/mdc3.13358;
RA   Zavala L., Ziegler G., Moron D.G., Garretto N.;
RT   "Dystonia-Deafness Syndrome: ACTB Pathogenic Variant in an Argentinean
RT   Family.";
RL   Mov. Disord. Clin. Pract. 9:122-124(2022).
CC   -!- FUNCTION: Actin is a highly conserved protein that polymerizes to
CC       produce filaments that form cross-linked networks in the cytoplasm of
CC       cells (PubMed:25255767, PubMed:29581253). Actin exists in both
CC       monomeric (G-actin) and polymeric (F-actin) forms, both forms playing
CC       key functions, such as cell motility and contraction (PubMed:29581253).
CC       In addition to their role in the cytoplasmic cytoskeleton, G- and F-
CC       actin also localize in the nucleus, and regulate gene transcription and
CC       motility and repair of damaged DNA (PubMed:29925947). Plays a role in
CC       the assembly of the gamma-tubulin ring complex (gTuRC), which regulates
CC       the minus-end nucleation of alpha-beta tubulin heterodimers that grow
CC       into microtubule protafilaments (PubMed:39321809, PubMed:38609661).
CC       Part of the ACTR1A/ACTB filament around which the dynactin complex is
CC       built (By similarity). The dynactin multiprotein complex activates the
CC       molecular motor dynein for ultra-processive transport along
CC       microtubules (By similarity). {ECO:0000250|UniProtKB:Q6QAQ1,
CC       ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:29581253,
CC       ECO:0000269|PubMed:29925947, ECO:0000269|PubMed:38609661,
CC       ECO:0000269|PubMed:39321809}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:25255767};
CC   -!- SUBUNIT: Polymerization of globular actin (G-actin) leads to a
CC       structural filament (F-actin) in the form of a two-stranded helix
CC       (PubMed:16685646, PubMed:28604741). Each actin can bind to 4 others
CC       (PubMed:16685646, PubMed:28604741). Identified in a IGF2BP1-dependent
CC       mRNP granule complex containing untranslated mRNAs (PubMed:17289661).
CC       Component of the BAF complex, which includes at least actin (ACTB),
CC       ARID1A, ARID1B/BAF250, SMARCA2, SMARCA4/BRG1, ACTL6A/BAF53,
CC       ACTL6B/BAF53B, SMARCE1/BAF57 SMARCC1/BAF155, SMARCC2/BAF170,
CC       SMARCB1/SNF5/INI1, and one or more of SMARCD1/BAF60A, SMARCD2/BAF60B,
CC       or SMARCD3/BAF60C (PubMed:18765789). In muscle cells, the BAF complex
CC       also contains DPF3 (PubMed:18765789). Found in a complex with XPO6,
CC       Ran, ACTB and PFN1 (PubMed:14592989). Interacts with PFN1
CC       (PubMed:10411937, PubMed:25255767). Interacts with XPO6 and EMD
CC       (PubMed:15328537). Interacts with ERBB2 (PubMed:21555369). Interacts
CC       with GCSAM (PubMed:17823310). Interacts with TBC1D21 (By similarity).
CC       Interacts with CPNE1 (via VWFA domain) and CPNE4 (via VWFA domain) (By
CC       similarity). Interacts with DHX9 (via C-terminus); this interaction is
CC       direct and mediates the attachment to nuclear ribonucleoprotein
CC       complexes (PubMed:11687588). Interacts with FAM107A (PubMed:21969592,
CC       PubMed:28604741). Associates with the gamma-tubulin ring complex
CC       (gTuRC) consisting of TUBGCP2, TUBGCP3, TUBGCP4, TUBGCP5 and TUBGCP6
CC       and gamma-tubulin TUBG1 or TUBG2; within the complex, interacts with
CC       TUBGCP3 and TUBGCP6 to form a luminal bridge with MZT1 that stabilizes
CC       the initial structure during complex assembly (PubMed:39321809,
CC       PubMed:38609661). Part of the ACTR1A/ACTB filament around which the
CC       dynactin complex is built (By similarity). The filament contains 8
CC       copies of ACTR1A and 1 ACTB (By similarity). Interacts with TPRN which
CC       forms ring-like structures in the stereocilium taper region; the
CC       interaction may stabilize stereocilia in inner ear hair cells (By
CC       similarity). Interacts with AMOTL2 (via N-terminus), the interaction
CC       facilitates binding of cell junction complexes to actin fibers in
CC       endothelial cells (By similarity). {ECO:0000250|UniProtKB:O18840,
CC       ECO:0000250|UniProtKB:P60710, ECO:0000250|UniProtKB:Q6QAQ1,
CC       ECO:0000269|PubMed:10411937, ECO:0000269|PubMed:11687588,
CC       ECO:0000269|PubMed:14592989, ECO:0000269|PubMed:15328537,
CC       ECO:0000269|PubMed:16685646, ECO:0000269|PubMed:17289661,
CC       ECO:0000269|PubMed:17823310, ECO:0000269|PubMed:18765789,
CC       ECO:0000269|PubMed:21555369, ECO:0000269|PubMed:21969592,
CC       ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:28604741,
CC       ECO:0000269|PubMed:38609661, ECO:0000269|PubMed:39321809}.
CC   -!- INTERACTION:
CC       P60709; P60709: ACTB; NbExp=16; IntAct=EBI-353944, EBI-353944;
CC       P60709; P63261: ACTG1; NbExp=16; IntAct=EBI-353944, EBI-351292;
CC       P60709; P05067: APP; NbExp=8; IntAct=EBI-353944, EBI-77613;
CC       P60709; Q9UQB8: BAIAP2; NbExp=2; IntAct=EBI-353944, EBI-525456;
CC       P60709; P40123: CAP2; NbExp=9; IntAct=EBI-353944, EBI-1051165;
CC       P60709; Q16543: CDC37; NbExp=3; IntAct=EBI-353944, EBI-295634;
CC       P60709; P23528: CFL1; NbExp=11; IntAct=EBI-353944, EBI-352733;
CC       P60709; Q549N0: CFL2; NbExp=3; IntAct=EBI-353944, EBI-10201319;
CC       P60709; Q9Y281: CFL2; NbExp=11; IntAct=EBI-353944, EBI-351218;
CC       P60709; P13569: CFTR; NbExp=6; IntAct=EBI-353944, EBI-349854;
CC       P60709; P60981: DSTN; NbExp=10; IntAct=EBI-353944, EBI-745191;
CC       P60709; Q8WTR2: DUSP19; NbExp=4; IntAct=EBI-353944, EBI-8654968;
CC       P60709; Q08426: EHHADH; NbExp=4; IntAct=EBI-353944, EBI-2339219;
CC       P60709; P50402: EMD; NbExp=2; IntAct=EBI-353944, EBI-489887;
CC       P60709; P04626: ERBB2; NbExp=10; IntAct=EBI-353944, EBI-641062;
CC       P60709; Q8TCJ0-2: FBXO25; NbExp=3; IntAct=EBI-353944, EBI-6264551;
CC       P60709; P11142: HSPA8; NbExp=2; IntAct=EBI-353944, EBI-351896;
CC       P60709; P83110: HTRA3; NbExp=5; IntAct=EBI-353944, EBI-2867394;
CC       P60709; P42858: HTT; NbExp=3; IntAct=EBI-353944, EBI-466029;
CC       P60709; O14950: MYL12B; NbExp=3; IntAct=EBI-353944, EBI-1642165;
CC       P60709; P14598: NCF1; NbExp=3; IntAct=EBI-353944, EBI-395044;
CC       P60709; P29474: NOS3; NbExp=3; IntAct=EBI-353944, EBI-1391623;
CC       P60709; Q92636: NSMAF; NbExp=2; IntAct=EBI-353944, EBI-2947053;
CC       P60709; Q96HA8: NTAQ1; NbExp=6; IntAct=EBI-353944, EBI-741158;
CC       P60709; P07737: PFN1; NbExp=3; IntAct=EBI-353944, EBI-713780;
CC       P60709; P78317: RNF4; NbExp=3; IntAct=EBI-353944, EBI-2340927;
CC       P60709; P37802: TAGLN2; NbExp=3; IntAct=EBI-353944, EBI-1056740;
CC       P60709; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-353944, EBI-717399;
CC       P60709; P13693: TPT1; NbExp=4; IntAct=EBI-353944, EBI-1783169;
CC       P60709; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-353944, EBI-10180829;
CC       P60709; Q9UBQ0-2: VPS29; NbExp=3; IntAct=EBI-353944, EBI-11141397;
CC       P60709; O75083: WDR1; NbExp=2; IntAct=EBI-353944, EBI-351917;
CC       P60709; P63104: YWHAZ; NbExp=3; IntAct=EBI-353944, EBI-347088;
CC       P60709; P08413: Camk2b; Xeno; NbExp=4; IntAct=EBI-353944, EBI-916155;
CC       P60709; Q8K4J6: Mrtfa; Xeno; NbExp=3; IntAct=EBI-353944, EBI-8291665;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:11687588, ECO:0000269|PubMed:17289661}. Nucleus
CC       {ECO:0000269|PubMed:11687588, ECO:0000269|PubMed:29925947}.
CC       Note=Localized in cytoplasmic mRNP granules containing untranslated
CC       mRNAs. {ECO:0000269|PubMed:17289661}.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798}.
CC   -!- PTM: Oxidation of Met-44 and Met-47 by MICALs (MICAL1, MICAL2 or
CC       MICAL3) to form methionine sulfoxide promotes actin filament
CC       depolymerization. MICAL1 and MICAL2 produce the (R)-S-oxide form. The
CC       (R)-S-oxide form is reverted by MSRB1 and MSRB2, which promote actin
CC       repolymerization. {ECO:0000269|PubMed:29343822}.
CC   -!- PTM: Monomethylation at Lys-84 (K84me1) regulates actin-myosin
CC       interaction and actomyosin-dependent processes (PubMed:23673617).
CC       Demethylation by ALKBH4 is required for maintaining actomyosin dynamics
CC       supporting normal cleavage furrow ingression during cytokinesis and
CC       cell migration (PubMed:23673617). {ECO:0000269|PubMed:23673617}.
CC   -!- PTM: Methylated at His-73 by SETD3 (PubMed:30526847, PubMed:30626964,
CC       PubMed:30785395, PubMed:31388018). Methylation at His-73 is required
CC       for smooth muscle contraction of the laboring uterus during delivery
CC       (By similarity). {ECO:0000250|UniProtKB:P60710,
CC       ECO:0000269|PubMed:30526847, ECO:0000269|PubMed:30626964,
CC       ECO:0000269|PubMed:30785395, ECO:0000269|PubMed:31388018}.
CC   -!- PTM: [Actin, cytoplasmic 1]: N-terminal cleavage of acetylated
CC       methionine of immature cytoplasmic actin by ACTMAP.
CC       {ECO:0000269|PubMed:36173861}.
CC   -!- PTM: [Actin, cytoplasmic 1, N-terminally processed]: N-terminal
CC       acetylation by NAA80 affects actin filament depolymerization and
CC       elongation, including elongation driven by formins (PubMed:29581253).
CC       In contrast, filament nucleation by the Arp2/3 complex is not affected
CC       (PubMed:29581253). {ECO:0000269|PubMed:29581253}.
CC   -!- PTM: (Microbial infection) Monomeric actin is cross-linked by
CC       V.cholerae toxins RtxA and VgrG1 in case of infection: bacterial toxins
CC       mediate the cross-link between Lys-50 of one monomer and Glu-270 of
CC       another actin monomer, resulting in formation of highly toxic actin
CC       oligomers that cause cell rounding (PubMed:19015515). The toxin can be
CC       highly efficient at very low concentrations by acting on formin
CC       homology family proteins: toxic actin oligomers bind with high affinity
CC       to formins and adversely affect both nucleation and elongation
CC       abilities of formins, causing their potent inhibition in both profilin-
CC       dependent and independent manners (PubMed:26228148).
CC       {ECO:0000305|PubMed:19015515, ECO:0000305|PubMed:26228148}.
CC   -!- DISEASE: Dystonia-deafness syndrome 1 (DDS1) [MIM:607371]: An autosomal
CC       dominant form of dystonia with juvenile onset, associated with
CC       congenital or childhood-onset sensorineural deafness. Dystonia is
CC       defined by the presence of sustained involuntary muscle contraction,
CC       often leading to abnormal postures. Some DDS1 patients have dysmorphic
CC       features, skeletal anomalies, and/or mild developmental delay with
CC       impaired intellectual development. {ECO:0000269|PubMed:16685646,
CC       ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:28487785,
CC       ECO:0000269|PubMed:29788902, ECO:0000269|PubMed:35005077}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Baraitser-Winter syndrome 1 (BRWS1) [MIM:243310]: A rare
CC       developmental disorder characterized by the combination of congenital
CC       ptosis, high-arched eyebrows, hypertelorism, ocular colobomata, and a
CC       brain malformation consisting of anterior-predominant lissencephaly.
CC       Other typical features include postnatal short stature and
CC       microcephaly, intellectual disability, seizures, and hearing loss.
CC       {ECO:0000269|PubMed:22366783, ECO:0000269|PubMed:30733661}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Thrombocytopenia 8, with dysmorphic features and developmental
CC       delay (THC8) [MIM:620475]: A form of thrombocytopenia, a hematologic
CC       disorder defined by a decrease in the number of platelets in
CC       circulating blood, resulting in the potential for increased bleeding
CC       and decreased ability for clotting. THC8 is an autosomal dominant form
CC       characterized by early-childhood onset of thrombocytopenia with
CC       platelet anisotropy. Affected individuals also have dysmorphic facial
CC       features and variable developmental delay with speech delay and mildly
CC       impaired intellectual development. {ECO:0000269|PubMed:10411937,
CC       ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:30315159,
CC       ECO:0000269|PubMed:30733661}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Becker nevus syndrome (BNS) [MIM:604919]: A syndrome
CC       characterized by the association of Becker nevi with musculoskeletal
CC       abnormalities, unilateral breast hypoplasia, intellectual disability,
CC       developmental delay, and cardiomyopathy. Becker nevus is a cutaneous
CC       hamartoma that appears in childhood as a unilateral tan patch and
CC       increases in thickness, pigmentation, and hair growth during
CC       adolescence. Histologically, epidermal acanthosis is accompanied by
CC       irregularly dispersed ectopic smooth muscle bundles and increased
CC       terminal hair follicles. Most cases are sporadic.
CC       {ECO:0000269|PubMed:28347698}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Congenital smooth muscle hamartoma, with or without
CC       hemihypertrophy (CSMH) [MIM:620470]: A benign skin lesion that usually
CC       presents as an indurated, slightly pigmented or flesh-colored plaque
CC       with perifollicular papules or coarse hair. Histopathologically, there
CC       is excessive proliferation of ectopic smooth muscle within the dermis.
CC       Hair follicles are normal in number and hyperkeratosis, acanthosis and
CC       hyperpigmentation of the basal cell layer can sometimes be seen.
CC       Rarely, CSMH is associated with hemihypertrophy.
CC       {ECO:0000269|PubMed:32170967}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: In vertebrates 3 main groups of actin isoforms, alpha,
CC       beta and gamma have been identified. The alpha actins are found in
CC       muscle tissues and are a major constituent of the contractile
CC       apparatus. The beta and gamma actins coexist in most cell types as
CC       components of the cytoskeleton and as mediators of internal cell
CC       motility. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the actin family. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be part of the MLL5-L complex, at
CC       least composed of KMT2E, STK38, PPP1CA, PPP1CB, PPP1CC, HCFC1, ACTB and
CC       OGT (PubMed:19377461). However, the corresponding article has been
CC       retracted (PubMed:24336203). {ECO:0000269|PubMed:19377461,
CC       ECO:0000269|PubMed:24336203}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/42959/ACTB";
CC   -!- WEB RESOURCE: Name=Mendelian genes actin, beta (ACTB); Note=Leiden Open
CC       Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/ACTB";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=On mar and motion - Issue
CC       208 of November 2018;
CC       URL="https://www.proteinspotlight.org/back_issues/208/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X00351; CAA25099.1; -; mRNA.
DR   EMBL; M10277; AAA51567.1; -; Genomic_DNA.
DR   EMBL; X63432; CAA45026.1; -; mRNA.
DR   EMBL; AY582799; AAS79319.1; -; Genomic_DNA.
DR   EMBL; AC006483; AAP22343.1; -; Genomic_DNA.
DR   EMBL; BC001301; AAH01301.1; -; mRNA.
DR   EMBL; BC002409; AAH02409.1; -; mRNA.
DR   EMBL; BC004251; AAH04251.1; -; mRNA.
DR   EMBL; BC008633; AAH08633.1; -; mRNA.
DR   EMBL; BC012854; AAH12854.1; -; mRNA.
DR   EMBL; BC013380; AAH13380.1; -; mRNA.
DR   EMBL; BC014861; AAH14861.1; -; mRNA.
DR   EMBL; BC016045; AAH16045.1; -; mRNA.
DR   EMBL; V00478; CAA23745.1; -; mRNA.
DR   CCDS; CCDS5341.1; -.
DR   PIR; A25168; ATHUB.
DR   RefSeq; NP_001092.1; NM_001101.5.
DR   PDB; 3BYH; EM; 12.00 A; A=2-375.
DR   PDB; 3D2U; X-ray; 2.21 A; C/G=170-178.
DR   PDB; 3J82; EM; 7.70 A; B/C/D=2-375.
DR   PDB; 3LUE; EM; -; A/B/C/D/E/F/G/H/I/J=2-375.
DR   PDB; 6ANU; EM; 7.00 A; A/B/C/D/E/F=1-375.
DR   PDB; 6ICT; X-ray; 1.95 A; E/G/H/I=66-88.
DR   PDB; 6ICV; X-ray; 2.15 A; C/D=66-88.
DR   PDB; 6LTJ; EM; 3.70 A; K=1-375.
DR   PDB; 6MBJ; X-ray; 1.78 A; Y/Z=66-80.
DR   PDB; 6MBK; X-ray; 1.69 A; Y/Z=66-80.
DR   PDB; 6MBL; X-ray; 2.20 A; Y=66-80.
DR   PDB; 6NBW; X-ray; 2.50 A; A=2-375.
DR   PDB; 6OX0; X-ray; 1.75 A; Y/Z=66-80.
DR   PDB; 6OX1; X-ray; 1.95 A; Y/Z=66-80.
DR   PDB; 6OX2; X-ray; 2.09 A; Y/Z=66-80.
DR   PDB; 6OX3; X-ray; 1.78 A; Y/Z=66-84.
DR   PDB; 6OX4; X-ray; 2.29 A; Y/Z=66-80.
DR   PDB; 6OX5; X-ray; 2.10 A; Y=66-83.
DR   PDB; 6V62; X-ray; 2.36 A; Y=66-88.
DR   PDB; 6V63; X-ray; 2.02 A; Y/Z=66-88.
DR   PDB; 6WK1; X-ray; 1.89 A; Y/Z=66-88.
DR   PDB; 6WK2; X-ray; 1.76 A; C/Y=66-88.
DR   PDB; 7AS4; EM; 4.13 A; 7=2-375.
DR   PDB; 7P1H; EM; 3.90 A; B=4-375.
DR   PDB; 7QJ6; EM; 7.80 A; e=1-375.
DR   PDB; 7QJ9; EM; 8.10 A; e=1-375.
DR   PDB; 7VDV; EM; 3.40 A; P=1-375.
DR   PDB; 7W28; X-ray; 1.79 A; P=66-81.
DR   PDB; 7W29; X-ray; 2.90 A; P=66-81.
DR   PDB; 7Y8R; EM; 4.40 A; J=1-375.
DR   PDB; 7ZTC; EM; 3.90 A; A/B/C/D/E/F/G/H=1-375.
DR   PDB; 7ZTD; EM; 4.60 A; A/B/C/D/E/F/G/H=1-375.
DR   PDB; 8COG; EM; 3.50 A; F=2-375.
DR   PDB; 8DNH; EM; 2.99 A; A/B/C/D=2-375.
DR   PDB; 8IB8; EM; 4.42 A; S=1-375.
DR   PDB; 8OI8; EM; 2.28 A; A/B/C/D/E=1-375.
DR   PDB; 8OID; EM; 2.30 A; A/B/C/D/E=1-375.
DR   PDB; 8QR1; EM; 2.40 A; B/G=1-375.
DR   PDB; 8RTT; EM; 3.56 A; A/B/C/D=1-375.
DR   PDB; 8RTY; EM; 6.25 A; A/B/C/D=2-375.
DR   PDB; 8RU2; EM; 3.49 A; B/C/D=2-375.
DR   PDB; 8RX1; EM; 3.57 A; 7=2-375.
DR   PDB; 8UAU; EM; 5.70 A; S=3-14.
DR   PDB; 8VRD; EM; 7.00 A; S=1-375.
DR   PDB; 8VRJ; EM; 7.70 A; 9=1-375.
DR   PDB; 8VRK; EM; 8.50 A; 9=1-375.
DR   PDB; 8X15; EM; 3.20 A; S/U=1-375.
DR   PDB; 8X19; EM; 3.20 A; S/U=1-375.
DR   PDB; 8X1C; EM; 3.20 A; S/U=1-375.
DR   PDB; 8XVG; EM; 9.40 A; K=1-375.
DR   PDB; 8XVT; EM; 3.20 A; K=1-375.
DR   PDB; 9B2Z; EM; 2.83 A; B=1-375.
DR   PDB; 9C57; EM; 2.75 A; J=1-375.
DR   PDB; 9C62; EM; 5.28 A; J=1-375.
DR   PDB; 9C6N; EM; 3.29 A; J=1-375.
DR   PDB; 9FJM; EM; 3.65 A; A/B/C/D=2-375.
DR   PDBsum; 3BYH; -.
DR   PDBsum; 3D2U; -.
DR   PDBsum; 3J82; -.
DR   PDBsum; 3LUE; -.
DR   PDBsum; 6ANU; -.
DR   PDBsum; 6ICT; -.
DR   PDBsum; 6ICV; -.
DR   PDBsum; 6LTJ; -.
DR   PDBsum; 6MBJ; -.
DR   PDBsum; 6MBK; -.
DR   PDBsum; 6MBL; -.
DR   PDBsum; 6NBW; -.
DR   PDBsum; 6OX0; -.
DR   PDBsum; 6OX1; -.
DR   PDBsum; 6OX2; -.
DR   PDBsum; 6OX3; -.
DR   PDBsum; 6OX4; -.
DR   PDBsum; 6OX5; -.
DR   PDBsum; 6V62; -.
DR   PDBsum; 6V63; -.
DR   PDBsum; 6WK1; -.
DR   PDBsum; 6WK2; -.
DR   PDBsum; 7AS4; -.
DR   PDBsum; 7P1H; -.
DR   PDBsum; 7QJ6; -.
DR   PDBsum; 7QJ9; -.
DR   PDBsum; 7VDV; -.
DR   PDBsum; 7W28; -.
DR   PDBsum; 7W29; -.
DR   PDBsum; 7Y8R; -.
DR   PDBsum; 7ZTC; -.
DR   PDBsum; 7ZTD; -.
DR   PDBsum; 8COG; -.
DR   PDBsum; 8DNH; -.
DR   PDBsum; 8IB8; -.
DR   PDBsum; 8OI8; -.
DR   PDBsum; 8OID; -.
DR   PDBsum; 8QR1; -.
DR   PDBsum; 8RTT; -.
DR   PDBsum; 8RTY; -.
DR   PDBsum; 8RU2; -.
DR   PDBsum; 8RX1; -.
DR   PDBsum; 8UAU; -.
DR   PDBsum; 8VRD; -.
DR   PDBsum; 8VRJ; -.
DR   PDBsum; 8VRK; -.
DR   PDBsum; 8X15; -.
DR   PDBsum; 8X19; -.
DR   PDBsum; 8X1C; -.
DR   PDBsum; 8XVG; -.
DR   PDBsum; 8XVT; -.
DR   PDBsum; 9B2Z; -.
DR   PDBsum; 9C57; -.
DR   PDBsum; 9C62; -.
DR   PDBsum; 9C6N; -.
DR   PDBsum; 9FJM; -.
DR   AlphaFoldDB; P60709; -.
DR   EMDB; EMD-0974; -.
DR   EMDB; EMD-11888; -.
DR   EMDB; EMD-13159; -.
DR   EMDB; EMD-16776; -.
DR   EMDB; EMD-16888; -.
DR   EMDB; EMD-16889; -.
DR   EMDB; EMD-18581; -.
DR   EMDB; EMD-18591; -.
DR   EMDB; EMD-18597; -.
DR   EMDB; EMD-18598; -.
DR   EMDB; EMD-18611; -.
DR   EMDB; EMD-18794; -.
DR   EMDB; EMD-19496; -.
DR   EMDB; EMD-19497; -.
DR   EMDB; EMD-19499; -.
DR   EMDB; EMD-19503; -.
DR   EMDB; EMD-27572; -.
DR   EMDB; EMD-31926; -.
DR   EMDB; EMD-37984; -.
DR   EMDB; EMD-37988; -.
DR   EMDB; EMD-37990; -.
DR   EMDB; EMD-38718; -.
DR   EMDB; EMD-43481; -.
DR   EMDB; EMD-43482; -.
DR   EMDB; EMD-43483; -.
DR   EMDB; EMD-44118; -.
DR   EMDB; EMD-45206; -.
DR   EMDB; EMD-45240; -.
DR   EMDB; EMD-45252; -.
DR   EMDB; EMD-50506; -.
DR   EMDB; EMD-8886; -.
DR   SASBDB; P60709; -.
DR   SMR; P60709; -.
DR   BioGRID; 106575; 1199.
DR   ComplexPortal; CPX-1164; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1194; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1195; Embryonic stem cell-specific SWI/SNF ATP-dependent chromatin remodeling complex.
DR   ComplexPortal; CPX-1196; Polybromo-associated SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B variant.
DR   ComplexPortal; CPX-1199; Polybromo-associated SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A variant.
DR   ComplexPortal; CPX-1201; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1202; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1203; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1204; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1A-SMARCA4 variant.
DR   ComplexPortal; CPX-1205; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1206; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1207; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1209; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1A-SMARCA4 variant.
DR   ComplexPortal; CPX-1210; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1211; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1212; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA4 variant.
DR   ComplexPortal; CPX-1213; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1215; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1216; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA4 variant.
DR   ComplexPortal; CPX-1217; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1218; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1219; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA4 variant.
DR   ComplexPortal; CPX-1220; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1221; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1222; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1A-SMARCA4 variant.
DR   ComplexPortal; CPX-1223; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1224; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-1225; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1226; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1A-SMARCA4 variant.
DR   ComplexPortal; CPX-1227; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1228; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA4 variant.
DR   ComplexPortal; CPX-4084; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6A-BICRA-SMARCA2 variant.
DR   ComplexPortal; CPX-4203; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6A-BICRAL-SMARCA2 variant.
DR   ComplexPortal; CPX-4206; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6A-BICRA-SMARCA4 variant.
DR   ComplexPortal; CPX-4207; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6A-BICRAL-SMARCA4 variant.
DR   ComplexPortal; CPX-4223; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6B-BICRA-SMARCA2 variant.
DR   ComplexPortal; CPX-4224; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6B-BICRAL-SMARCA2 variant.
DR   ComplexPortal; CPX-4225; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6B-BICRA-SMARCA4 variant.
DR   ComplexPortal; CPX-4226; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6B-BICRAL-SMARCA4 variant.
DR   ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex.
DR   CORUM; P60709; -.
DR   DIP; DIP-29686N; -.
DR   FunCoup; P60709; 2855.
DR   IntAct; P60709; 516.
DR   MINT; P60709; -.
DR   STRING; 9606.ENSP00000494750; -.
DR   ChEMBL; CHEMBL2062353; -.
DR   DrugBank; DB12695; Phenethyl Isothiocyanate.
DR   DrugBank; DB04216; Quercetin.
DR   CarbonylDB; P60709; -.
DR   GlyCosmos; P60709; 6 sites, 2 glycans.
DR   GlyGen; P60709; 8 sites, 1 N-linked glycan (1 site), 2 O-linked glycans (7 sites).
DR   iPTMnet; P60709; -.
DR   MetOSite; P60709; -.
DR   PhosphoSitePlus; P60709; -.
DR   SwissPalm; P60709; -.
DR   BioMuta; ACTB; -.
DR   DMDM; 46397333; -.
DR   REPRODUCTION-2DPAGE; P60709; -.
DR   jPOST; P60709; -.
DR   MassIVE; P60709; -.
DR   PaxDb; 9606-ENSP00000349960; -.
DR   PeptideAtlas; P60709; -.
DR   PRIDE; P60709; -.
DR   ProteomicsDB; 57224; -.
DR   Pumba; P60709; -.
DR   TopDownProteomics; P60709; -.
DR   ABCD; P60709; 4 sequenced antibodies.
DR   Antibodypedia; 3623; 2078 antibodies from 59 providers.
DR   DNASU; 60; -.
DR   Ensembl; ENST00000493945.6; ENSP00000494269.1; ENSG00000075624.17.
DR   Ensembl; ENST00000642480.2; ENSP00000495995.2; ENSG00000075624.17.
DR   Ensembl; ENST00000646664.1; ENSP00000494750.1; ENSG00000075624.17.
DR   Ensembl; ENST00000674681.1; ENSP00000502821.1; ENSG00000075624.17.
DR   Ensembl; ENST00000675515.1; ENSP00000501862.1; ENSG00000075624.17.
DR   GeneID; 60; -.
DR   KEGG; hsa:60; -.
DR   MANE-Select; ENST00000646664.1; ENSP00000494750.1; NM_001101.5; NP_001092.1.
DR   AGR; HGNC:132; -.
DR   CTD; 60; -.
DR   DisGeNET; 60; -.
DR   GeneCards; ACTB; -.
DR   GeneReviews; ACTB; -.
DR   HGNC; HGNC:132; ACTB.
DR   HPA; ENSG00000075624; Low tissue specificity.
DR   MalaCards; ACTB; -.
DR   MIM; 102630; gene.
DR   MIM; 243310; phenotype.
DR   MIM; 604919; phenotype.
DR   MIM; 607371; phenotype.
DR   MIM; 620470; phenotype.
DR   MIM; 620475; phenotype.
DR   neXtProt; NX_P60709; -.
DR   OpenTargets; ENSG00000075624; -.
DR   Orphanet; 674653; Actinomyopathy-associated syndromic thrombocytopenia.
DR   Orphanet; 2995; Baraitser-Winter cerebrofrontofacial syndrome.
DR   Orphanet; 64755; Becker nevus syndrome.
DR   Orphanet; 79107; Developmental malformations-deafness-dystonia syndrome.
DR   Orphanet; 673556; Pseudomyogenic hemangioendothelioma.
DR   PharmGKB; PA24457; -.
DR   VEuPathDB; HostDB:ENSG00000075624; -.
DR   eggNOG; KOG0676; Eukaryota.
DR   GeneTree; ENSGT00950000182960; -.
DR   HOGENOM; CLU_027965_0_2_1; -.
DR   InParanoid; P60709; -.
DR   OMA; KCDESIC; -.
DR   OrthoDB; 9816605at2759; -.
DR   PAN-GO; P60709; 10 GO annotations based on evolutionary models.
DR   PhylomeDB; P60709; -.
DR   TreeFam; TF354237; -.
DR   PathwayCommons; P60709; -.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-190873; Gap junction degradation.
DR   Reactome; R-HSA-196025; Formation of annular gap junctions.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-389957; Prefoldin mediated transfer of substrate to CCT/TriC.
DR   Reactome; R-HSA-390450; Folding of actin by CCT/TriC.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-418990; Adherens junctions interactions.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-446353; Cell-extracellular matrix interactions.
DR   Reactome; R-HSA-5250924; B-WICH complex positively regulates rRNA expression.
DR   Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   Reactome; R-HSA-5696394; DNA Damage Recognition in GG-NER.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-9035034; RHOF GTPase cycle.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   Reactome; R-HSA-9662360; Sensory processing of sound by inner hair cells of the cochlea.
DR   Reactome; R-HSA-9662361; Sensory processing of sound by outer hair cells of the cochlea.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   Reactome; R-HSA-9845323; Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs).
DR   Reactome; R-HSA-9913351; Formation of the dystrophin-glycoprotein complex (DGC).
DR   SignaLink; P60709; -.
DR   SIGNOR; P60709; -.
DR   BioGRID-ORCS; 60; 541 hits in 1170 CRISPR screens.
DR   CD-CODE; 232F8A39; P-body.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; F85A2E29; IMP1 RNP granule.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; ACTB; human.
DR   EvolutionaryTrace; P60709; -.
DR   GeneWiki; Beta-actin; -.
DR   GenomeRNAi; 60; -.
DR   Pharos; P60709; Tbio.
DR   PRO; PR:P60709; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P60709; protein.
DR   Bgee; ENSG00000075624; Expressed in saphenous vein and 212 other cell types or tissues.
DR   ExpressionAtlas; P60709; baseline and differential.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005884; C:actin filament; IBA:GO_Central.
DR   GO; GO:0005912; C:adherens junction; IDA:ARUK-UCL.
DR   GO; GO:0043296; C:apical junction complex; IDA:ARUK-UCL.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0140092; C:bBAF complex; NAS:ComplexPortal.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0035060; C:brahma complex; NAS:ComplexPortal.
DR   GO; GO:0005903; C:brush border; IEA:Ensembl.
DR   GO; GO:0044305; C:calyx of Held; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IMP:ARUK-UCL.
DR   GO; GO:0000785; C:chromatin; HDA:UniProtKB.
DR   GO; GO:0030863; C:cortical cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0097433; C:dense body; ISS:AgBase.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0140288; C:GBAF complex; NAS:ComplexPortal.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0000776; C:kinetochore; NAS:ComplexPortal.
DR   GO; GO:0030027; C:lamellipodium; IDA:ARUK-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0071565; C:nBAF complex; NAS:ComplexPortal.
DR   GO; GO:0071564; C:npBAF complex; NAS:ComplexPortal.
DR   GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0016363; C:nuclear matrix; NAS:ComplexPortal.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0000786; C:nucleosome; IDA:ComplexPortal.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:AgBase.
DR   GO; GO:0098871; C:postsynaptic actin cytoskeleton; IDA:SynGO.
DR   GO; GO:0098793; C:presynapse; TAS:ARUK-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0016586; C:RSC-type complex; NAS:ComplexPortal.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0016514; C:SWI/SNF complex; NAS:ComplexPortal.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0070160; C:tight junction; IDA:ARUK-UCL.
DR   GO; GO:0031982; C:vesicle; HDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019894; F:kinesin binding; IPI:UniProtKB.
DR   GO; GO:0050998; F:nitric-oxide synthase binding; IPI:BHF-UCL.
DR   GO; GO:0030235; F:nitric-oxide synthase regulator activity; IDA:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0098973; F:structural constituent of postsynaptic actin cytoskeleton; IDA:SynGO.
DR   GO; GO:0030957; F:Tat protein binding; IPI:BHF-UCL.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0141108; F:transporter regulator activity; IGI:ARUK-UCL.
DR   GO; GO:0034333; P:adherens junction assembly; IMP:ARUK-UCL.
DR   GO; GO:0045176; P:apical protein localization; IMP:ARUK-UCL.
DR   GO; GO:0007409; P:axonogenesis; IBA:GO_Central.
DR   GO; GO:0048870; P:cell motility; IMP:UniProtKB.
DR   GO; GO:0072749; P:cellular response to cytochalasin B; IMP:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; HDA:GO_Central.
DR   GO; GO:0007010; P:cytoskeleton organization; ISS:ARUK-UCL.
DR   GO; GO:0007163; P:establishment or maintenance of cell polarity; IMP:ARUK-UCL.
DR   GO; GO:0035633; P:maintenance of blood-brain barrier; NAS:ARUK-UCL.
DR   GO; GO:0001738; P:morphogenesis of a polarized epithelium; IMP:ARUK-UCL.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0070527; P:platelet aggregation; HMP:UniProtKB.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; NAS:ComplexPortal.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal.
DR   GO; GO:2000781; P:positive regulation of double-strand break repair; NAS:ComplexPortal.
DR   GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:ComplexPortal.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; NAS:ComplexPortal.
DR   GO; GO:0051623; P:positive regulation of norepinephrine uptake; TAS:ARUK-UCL.
DR   GO; GO:1902459; P:positive regulation of stem cell population maintenance; NAS:ComplexPortal.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0071896; P:protein localization to adherens junction; IMP:ARUK-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; NAS:ComplexPortal.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:ComplexPortal.
DR   GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal.
DR   GO; GO:0070316; P:regulation of G0 to G1 transition; NAS:ComplexPortal.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; NAS:ComplexPortal.
DR   GO; GO:0030071; P:regulation of mitotic metaphase/anaphase transition; NAS:ComplexPortal.
DR   GO; GO:0051621; P:regulation of norepinephrine uptake; IGI:ARUK-UCL.
DR   GO; GO:2000819; P:regulation of nucleotide-excision repair; NAS:ComplexPortal.
DR   GO; GO:1903076; P:regulation of protein localization to plasma membrane; IMP:ARUK-UCL.
DR   GO; GO:1900242; P:regulation of synaptic vesicle endocytosis; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; NAS:ComplexPortal.
DR   GO; GO:0150111; P:regulation of transepithelial transport; IMP:ARUK-UCL.
DR   GO; GO:0021762; P:substantia nigra development; HEP:UniProtKB.
DR   CDD; cd10224; ASKHA_NBD_actin; 1.
DR   FunFam; 3.30.420.40:FF:000131; Actin, alpha skeletal muscle; 1.
DR   FunFam; 3.30.420.40:FF:000291; Actin, alpha skeletal muscle; 1.
DR   FunFam; 3.90.640.10:FF:000047; Actin, alpha skeletal muscle; 1.
DR   FunFam; 3.30.420.40:FF:000058; Putative actin-related protein 5; 1.
DR   Gene3D; 3.30.420.40; -; 2.
DR   Gene3D; 3.90.640.10; Actin, Chain A, domain 4; 1.
DR   InterPro; IPR004000; Actin.
DR   InterPro; IPR020902; Actin/actin-like_CS.
DR   InterPro; IPR004001; Actin_CS.
DR   InterPro; IPR043129; ATPase_NBD.
DR   PANTHER; PTHR11937; ACTIN; 1.
DR   Pfam; PF00022; Actin; 1.
DR   PRINTS; PR00190; ACTIN.
DR   SMART; SM00268; ACTIN; 1.
DR   SUPFAM; SSF53067; Actin-like ATPase domain; 2.
DR   PROSITE; PS00406; ACTINS_1; 1.
DR   PROSITE; PS00432; ACTINS_2; 1.
DR   PROSITE; PS01132; ACTINS_ACT_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cytoplasm; Cytoskeleton; Deafness;
KW   Direct protein sequencing; Disease variant; Dystonia; Hydrolase;
KW   Intellectual disability; Isopeptide bond; Methylation; Nucleotide-binding;
KW   Nucleus; Oxidation; Proteomics identification; Reference proteome;
KW   Ubl conjugation.
FT   CHAIN           1..375
FT                   /note="Actin, cytoplasmic 1"
FT                   /id="PRO_0000367073"
FT   INIT_MET        1
FT                   /note="Removed; alternate"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0000269|PubMed:36173861, ECO:0000269|Ref.8,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378, ECO:0007744|PubMed:25944712"
FT   CHAIN           2..375
FT                   /note="Actin, cytoplasmic 1, N-terminally processed"
FT                   /evidence="ECO:0000305|PubMed:29581253"
FT                   /id="PRO_0000000771"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|PubMed:36173861,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         2
FT                   /note="N-acetylaspartate; in Actin, cytoplasmic 1, N-
FT                   terminally processed"
FT                   /evidence="ECO:0000269|PubMed:29581253,
FT                   ECO:0000269|PubMed:30028079, ECO:0000269|Ref.8,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378, ECO:0007744|PubMed:25944712"
FT   MOD_RES         44
FT                   /note="Methionine (R)-sulfoxide"
FT                   /evidence="ECO:0000269|PubMed:29343822"
FT   MOD_RES         47
FT                   /note="Methionine (R)-sulfoxide"
FT                   /evidence="ECO:0000269|PubMed:29343822"
FT   MOD_RES         73
FT                   /note="Tele-methylhistidine"
FT                   /evidence="ECO:0000269|PubMed:30526847,
FT                   ECO:0000269|PubMed:30626964, ECO:0000269|PubMed:30785395,
FT                   ECO:0000269|PubMed:31388018, ECO:0000269|PubMed:32503840"
FT   MOD_RES         84
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|PubMed:23673617"
FT   CROSSLNK        50
FT                   /note="(Microbial infection) Isoglutamyl lysine isopeptide
FT                   (Lys-Glu) (interchain with E-270); by Vibrio toxins RtxA
FT                   and VgrG1"
FT                   /evidence="ECO:0000305|PubMed:19015515"
FT   CROSSLNK        270
FT                   /note="(Microbial infection) Isoglutamyl lysine isopeptide
FT                   (Glu-Lys) (interchain with K-50); by Vibrio toxins RtxA and
FT                   VgrG1"
FT                   /evidence="ECO:0000305|PubMed:19015515"
FT   VARIANT         12
FT                   /note="N -> D (in BRWS1; dbSNP:rs281875331)"
FT                   /evidence="ECO:0000269|PubMed:22366783"
FT                   /id="VAR_067810"
FT   VARIANT         65
FT                   /note="L -> V (in BRWS1; dbSNP:rs281875332)"
FT                   /evidence="ECO:0000269|PubMed:22366783"
FT                   /id="VAR_067811"
FT   VARIANT         70
FT                   /note="P -> A (in BRWS1; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:30733661"
FT                   /id="VAR_088861"
FT   VARIANT         111
FT                   /note="N -> D (in CSMH; uncertain significance; somatic
FT                   variant)"
FT                   /evidence="ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088862"
FT   VARIANT         137
FT                   /note="Q -> H (in CSMH; uncertain significance; somatic
FT                   variant)"
FT                   /evidence="ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088863"
FT   VARIANT         146
FT                   /note="G -> A (in CSMH; somatic variant)"
FT                   /evidence="ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088864"
FT   VARIANT         146
FT                   /note="G -> D (in CSMH; somatic variant)"
FT                   /evidence="ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088865"
FT   VARIANT         146
FT                   /note="G -> S (in CSMH; somatic variant)"
FT                   /evidence="ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088866"
FT   VARIANT         146
FT                   /note="G -> V (in CSMH; somatic variant)"
FT                   /evidence="ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088867"
FT   VARIANT         147
FT                   /note="R -> C (in BNS and CSMH; also found in isolated
FT                   non-syndromic Becker nevi; somatic variant)"
FT                   /evidence="ECO:0000269|PubMed:28347698,
FT                   ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088868"
FT   VARIANT         147
FT                   /note="R -> S (in CSMH; also found in isolated
FT                   non-syndromic Becker nevi; somatic variant)"
FT                   /evidence="ECO:0000269|PubMed:28347698,
FT                   ECO:0000269|PubMed:32170967"
FT                   /id="VAR_088869"
FT   VARIANT         171
FT                   /note="L -> F (in THC8; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:30733661"
FT                   /id="VAR_088870"
FT   VARIANT         183
FT                   /note="R -> W (in DDS1; likely pathogenic; results in
FT                   reduced actin polymerization rate and increased
FT                   depolymerization; results in higher ATP hydrolysis compared
FT                   to the wild type; does not affect thermal stability;
FT                   modifies cell response to latrunculin A;
FT                   dbSNP:rs104894003)"
FT                   /evidence="ECO:0000269|PubMed:16685646,
FT                   ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:28487785,
FT                   ECO:0000269|PubMed:29788902, ECO:0000269|PubMed:35005077"
FT                   /id="VAR_030026"
FT   VARIANT         196
FT                   /note="R -> C (in BRWS1; dbSNP:rs281875333)"
FT                   /evidence="ECO:0000269|PubMed:22366783"
FT                   /id="VAR_067812"
FT   VARIANT         196
FT                   /note="R -> H (in BRWS1; dbSNP:rs281875334)"
FT                   /evidence="ECO:0000269|PubMed:22366783"
FT                   /id="VAR_067813"
FT   VARIANT         243
FT                   /note="P -> L (in dbSNP:rs11546899)"
FT                   /id="VAR_048185"
FT   VARIANT         313
FT                   /note="M -> R (in THC8; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:30315159"
FT                   /id="VAR_088871"
FT   VARIANT         338..341
FT                   /note="Missing (in THC8; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:30315159"
FT                   /id="VAR_088872"
FT   VARIANT         364
FT                   /note="E -> K (in THC8; uncertain significance; results in
FT                   reduced actin polymerization rate without affecting
FT                   depolymerization; has no effect on ATP hydrolysis rate;
FT                   does not affect thermal stability)"
FT                   /evidence="ECO:0000269|PubMed:10411937,
FT                   ECO:0000269|PubMed:25255767"
FT                   /id="VAR_088873"
FT   MUTAGEN         69
FT                   /note="Y->A: Decreased interaction with SETD3."
FT                   /evidence="ECO:0000269|PubMed:30785395"
FT   MUTAGEN         71
FT                   /note="I->A: Decreased interaction with SETD3."
FT                   /evidence="ECO:0000269|PubMed:30785395"
FT   MUTAGEN         71
FT                   /note="I->A: Impaired methylation by SETD3."
FT                   /evidence="ECO:0000269|PubMed:30626964"
FT   MUTAGEN         73
FT                   /note="H->A: Abolished methylation by SETD3."
FT                   /evidence="ECO:0000269|PubMed:30785395"
FT   MUTAGEN         73
FT                   /note="H->K: Weak methylation by a A-256 or V-256 SETD3
FT                   mutant. High methylation by a F-256 and A-274 SETD3
FT                   mutant."
FT                   /evidence="ECO:0000269|PubMed:31388018,
FT                   ECO:0000269|PubMed:32503840"
FT   MUTAGEN         74
FT                   /note="G->A: Impaired methylation by SETD3."
FT                   /evidence="ECO:0000269|PubMed:30626964"
FT   MUTAGEN         79
FT                   /note="W->E: Does not affect methylation by SETD3."
FT                   /evidence="ECO:0000269|PubMed:30626964"
FT   MUTAGEN         80
FT                   /note="D->A: Decreased interaction with SETD3."
FT                   /evidence="ECO:0000269|PubMed:30785395"
FT   MUTAGEN         81
FT                   /note="D->A: Decreased interaction with SETD3."
FT                   /evidence="ECO:0000269|PubMed:30785395"
FT   MUTAGEN         82
FT                   /note="M->A: Decreased interaction with SETD3."
FT                   /evidence="ECO:0000269|PubMed:30785395"
FT   CONFLICT        97
FT                   /note="A -> P (in Ref. 6; AAH16045)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        116
FT                   /note="R -> L (in Ref. 6; AAH12854)"
FT                   /evidence="ECO:0000305"
FT   TURN            3..5
FT                   /evidence="ECO:0007829|PDB:8DNH"
FT   STRAND          8..12
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          14..21
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          24..26
FT                   /evidence="ECO:0007829|PDB:8COG"
FT   STRAND          28..32
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          35..38
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          40..42
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          44..47
FT                   /evidence="ECO:0007829|PDB:8DNH"
FT   STRAND          51..54
FT                   /evidence="ECO:0007829|PDB:8RU2"
FT   HELIX           56..60
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          68..70
FT                   /evidence="ECO:0007829|PDB:6MBK"
FT   STRAND          75..77
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   TURN            81..83
FT                   /evidence="ECO:0007829|PDB:6OX3"
FT   TURN            92..94
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   TURN            98..100
FT                   /evidence="ECO:0007829|PDB:8OID"
FT   STRAND          103..107
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           113..125
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          130..136
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           137..144
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          148..155
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          160..166
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           172..174
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          176..179
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           182..193
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           194..196
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           203..216
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           223..230
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   TURN            231..233
FT                   /evidence="ECO:0007829|PDB:7VDV"
FT   HELIX           234..236
FT                   /evidence="ECO:0007829|PDB:8XVT"
FT   STRAND          238..241
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          243..246
FT                   /evidence="ECO:0007829|PDB:7VDV"
FT   STRAND          247..251
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           253..259
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   TURN            260..262
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           264..267
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           274..283
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           287..289
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           290..294
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          297..301
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           302..304
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           309..320
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:8DNH"
FT   HELIX           335..337
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           338..346
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   TURN            353..355
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   STRAND          356..358
FT                   /evidence="ECO:0007829|PDB:8XVT"
FT   HELIX           359..365
FT                   /evidence="ECO:0007829|PDB:8OI8"
FT   HELIX           366..370
FT                   /evidence="ECO:0007829|PDB:8OI8"
SQ   SEQUENCE   375 AA;  41737 MW;  6AFD05CA94E360E2 CRC64;
     MDDDIAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK DSYVGDEAQS
     KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE HPVLLTEAPL NPKANREKMT
     QIMFETFNTP AMYVAIQAVL SLYASGRTTG IVMDSGDGVT HTVPIYEGYA LPHAILRLDL
     AGRDLTDYLM KILTERGYSF TTTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY
     ELPDGQVITI GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS
     GGTTMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS TFQQMWISKQ
     EYDESGPSIV HRKCF
//
